Modelling infectious disease to support human health.
David M TobinPublished in: Disease models & mechanisms (2022)
During the current COVID-19 pandemic, there has been renewed scientific and public focus on understanding the pathogenesis of infectious diseases and investigating vaccines and therapies to combat them. In addition to the tragic toll of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we also recognize increased threats from antibiotic-resistant bacterial strains, the effects of climate change on the prevalence and spread of human pathogens, and the recalcitrance of other infectious diseases - including tuberculosis, malaria, human immunodeficiency virus (HIV) and fungal infections - that continue to cause millions of deaths annually. Large amounts of funding have rightly been redirected toward vaccine development and clinical trials for COVID-19, but we must continue to pursue fundamental and translational research on other pathogens and host immunity. Now more than ever, we need to support the next generation of researchers to develop and utilize models of infectious disease that serve as engines of discovery, innovation and therapy.
Keyphrases
- infectious diseases
- human immunodeficiency virus
- respiratory syndrome coronavirus
- sars cov
- human health
- climate change
- antiretroviral therapy
- hepatitis c virus
- coronavirus disease
- risk assessment
- hiv aids
- clinical trial
- hiv infected
- gram negative
- hiv positive
- endothelial cells
- antimicrobial resistance
- small molecule
- healthcare
- mycobacterium tuberculosis
- escherichia coli
- risk factors
- induced pluripotent stem cells
- hiv testing
- multidrug resistant
- adverse drug
- pulmonary tuberculosis
- mental health
- randomized controlled trial
- high throughput
- phase iii
- replacement therapy
- men who have sex with men
- cell wall
- south africa